30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Current & Critical

DePuy Synthes Names New Leadership in JNJ Reorganization

Johnson & Johnson (JNJ) combined its orthopaedics and surgery divisions into a single Medical Device group and named new leadership, a strategic decision that thus far comes with little detail.

Ernie W. Knewitz, Vice President, Media Relations at JNJ told ORTHOWORLD that the move will assist the company in better serving the needs of surgeons and patients and it coincides with Michel Orsinger, Worldwide Chairman, Global Orthopaedics, informing leadership that he has chosen to pursue other opportunities.

Gary Pruden, who previously led the company’s surgery division, was named Worldwide Chairman, JNJ Medical Devices. Orsinger will support Pruden as the businesses transition to one unit in the coming months. Orsinger took the helm of the orthopaedics group in 2012, moving from his role as CEO of Synthes when JNJ acquired Synthes for $19.7 million and integrated the Swiss company with DePuy. 

JNJ has not released further information on the integration of the businesses.

Gary Pruden

What is known is that Pruden’s rise to leadership came on the sales side of several JNJ businesses. He joined the company in 1985 and held senior sales and marketing positions before being named President of Janssen-Ortho Inc. in 2004, Worldwide President of Ethicon Products in 2006 and head of the Global Surgery Group in 2012.

The Global Surgery Group includes Ethicon Surgical Care (sutures, staples, etc.), Ethicon Energy (cutting solutions), Ethicon Biosurgery (devices to control bleeding), Cardiovascular Care products (catheters, etc.), Mentor (aesthetics), Accelarent (less-invasive ear, nose and throat procedure solutions) and Sterilmed (medical device reprocessing).

ORTHOWORLD estimates that DePuy Synthes, which posted revenue of $9.67 billion in 2014, holds similar rankings in orthopaedic markets, only dropping to third in the arthroscopy/soft tissue segment.*The group achieved revenue of more than $11 billion in 2014, and the company reports 80 percent of the group’s sales come from businesses that have grown to the No. 1 or No. 2 global market share position.

The move reflects JNJ leadership’s previous comments regarding implementing new approaches to more easily, more holistically work with partners—hospital systems, governments—around the world.

“When you think about the depth and the breadth that we have from orthopaedics to surgery to the pharmaceutical group, our ability not only to contract but to fundamentally partner, price and work collaboratively in a different construct, it offers us a unique and exciting opportunity to be part of the solution in healthcare as it continues to change around the globe,” JNJ Chairman and CEO Alex Gorsky said during the 4Q14 earnings call.

Carolyn LaWell is ORTHOWORLD’s Content Manager. She can be reached by email

*More information on DePuy Synthes can be found in
Download yours here.

For a full, detailed overview of DePuy Synthes and the other top players,
download the Orthopaedic Device Company Profiles: Top Performers.
Members receive a special rate.